---
document_datetime: 2025-12-02 04:50:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/grasustek.html
document_name: grasustek.html
version: success
processing_time: 0.1025564
conversion_datetime: 2025-12-25 10:48:42.34418
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Grasustek

[RSS](/en/individual-human-medicine.xml/67211)

##### Authorised

This medicine is authorised for use in the European Union

pegfilgrastim Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Grasustek](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Grasustek is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer chemotherapy and can leave patients vulnerable to infections.

It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever due to an infection).

Grasustek is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, which can develop into leukaemia).

Grasustek is a 'biosimilar medicine'. This means that Grasustek is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Grasustek is Neulasta.

Grasustek contains the active substance pegfilgrastim.

Expand section

Collapse section

## How is Grasustek used?

Grasustek can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders. It is available as a prefilled syringe containing a solution for injection under the skin. Grasustek is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of cancer treatment. Patients can inject themselves if they have been trained appropriately.

For more information about using Grasustek, see the package leaflet or contact your doctor or pharmacist.

## How does Grasustek work?

The active substance in Grasustek, pegfilgrastim, is a form of filgrastim, which is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF). Filgrastim works by encouraging the bone marrow to produce more white blood cells, increasing white blood cell counts and so treating neutropenia.

Filgrastim has been available in other medicines in the EU for a number of years. In Grasustek, filgrastim has been 'pegylated' (attached to a chemical called polyethylene glycol). This slows down the removal of filgrastim from the body, allowing the medicine to be given less often.

## What benefits of Grasustek have been shown in studies?

Laboratory studies comparing Grasustek with Neulasta have shown that the active substance in Grasustek is highly similar to that in Neulasta in terms of structure, purity and biological activity. Studies have also shown that giving Grasustek produces similar levels of the active substance in the body to giving Neulasta.

In addition, a study involving 248 patients who had chemotherapy after surgery for breast cancer showed that Grasustek was as effective as Neulasta in reducing the duration of neutropenia. Severe neutropenia lasted just over one-and-a-half days on average with both medicines.

Because Grasustek is a biosimilar medicine, the studies on effectiveness and safety of pegfilgrastim carried out with Neulasta do not all need to be repeated for Grasustek.

## What are the risks associated with Grasustek?

The safety of Grasustek has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Neulasta. The most common side effect with Grasustek (which may affect more than 1 in 10 people) is pain in the bones. Pain in muscles is also common. For the full list of side effects and restrictions with Grasustek, see the package leaflet.

## Why is Grasustek authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Grasustek has a highly similar structure, purity and biological activity to Neulasta and is distributed in the body in the same way. In addition, studies in breast cancer patients undergoing chemotherapy have shown that the effectiveness of Grasustek in reducing the duration of neutropenia is equivalent to that of Neulasta.

All these data were considered sufficient to conclude that Grasustek will behave in the same way as Neulasta in terms of effectiveness and safety in its authorised uses. Therefore, the Agency's view was that, as for Neulasta, the benefits of Grasustek outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Grasustek?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Grasustek have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Grasustek are continuously monitored. Side effects reported with Grasustek are carefully evaluated and any necessary action taken to protect patients.

## Other information about Grasustek

Grasustek received a marketing authorisation valid throughout the EU on 20 June 2019.

Grasustek : EPAR - Medicine overview

Reference Number: EMA/360643/2019

English (EN) (107.84 KB - PDF)

**First published:** 28/06/2019

[View](/en/documents/overview/grasustek-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-635)

български (BG) (125.8 KB - PDF)

**First published:**

28/06/2019

[View](/bg/documents/overview/grasustek-epar-medicine-overview_bg.pdf)

español (ES) (102.58 KB - PDF)

**First published:**

28/06/2019

[View](/es/documents/overview/grasustek-epar-medicine-overview_es.pdf)

čeština (CS) (123.52 KB - PDF)

**First published:**

28/06/2019

[View](/cs/documents/overview/grasustek-epar-medicine-overview_cs.pdf)

dansk (DA) (100.2 KB - PDF)

**First published:**

28/06/2019

[View](/da/documents/overview/grasustek-epar-medicine-overview_da.pdf)

Deutsch (DE) (104.61 KB - PDF)

**First published:**

28/06/2019

[View](/de/documents/overview/grasustek-epar-medicine-overview_de.pdf)

eesti keel (ET) (90.65 KB - PDF)

**First published:**

28/06/2019

[View](/et/documents/overview/grasustek-epar-medicine-overview_et.pdf)

ελληνικά (EL) (124.65 KB - PDF)

**First published:**

28/06/2019

[View](/el/documents/overview/grasustek-epar-medicine-overview_el.pdf)

français (FR) (102.92 KB - PDF)

**First published:**

28/06/2019

[View](/fr/documents/overview/grasustek-epar-medicine-overview_fr.pdf)

hrvatski (HR) (120.1 KB - PDF)

**First published:**

28/06/2019

[View](/hr/documents/overview/grasustek-epar-medicine-overview_hr.pdf)

italiano (IT) (100.95 KB - PDF)

**First published:**

28/06/2019

[View](/it/documents/overview/grasustek-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (126.76 KB - PDF)

**First published:**

28/06/2019

[View](/lv/documents/overview/grasustek-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (120.92 KB - PDF)

**First published:**

28/06/2019

[View](/lt/documents/overview/grasustek-epar-medicine-overview_lt.pdf)

magyar (HU) (121.9 KB - PDF)

**First published:**

28/06/2019

[View](/hu/documents/overview/grasustek-epar-medicine-overview_hu.pdf)

Malti (MT) (123.71 KB - PDF)

**First published:**

28/06/2019

[View](/mt/documents/overview/grasustek-epar-medicine-overview_mt.pdf)

Nederlands (NL) (101.82 KB - PDF)

**First published:**

28/06/2019

[View](/nl/documents/overview/grasustek-epar-medicine-overview_nl.pdf)

polski (PL) (123.85 KB - PDF)

**First published:**

28/06/2019

[View](/pl/documents/overview/grasustek-epar-medicine-overview_pl.pdf)

português (PT) (102.67 KB - PDF)

**First published:**

28/06/2019

[View](/pt/documents/overview/grasustek-epar-medicine-overview_pt.pdf)

română (RO) (120.43 KB - PDF)

**First published:**

28/06/2019

[View](/ro/documents/overview/grasustek-epar-medicine-overview_ro.pdf)

slovenčina (SK) (122.99 KB - PDF)

**First published:**

28/06/2019

[View](/sk/documents/overview/grasustek-epar-medicine-overview_sk.pdf)

slovenščina (SL) (120.41 KB - PDF)

**First published:**

28/06/2019

[View](/sl/documents/overview/grasustek-epar-medicine-overview_sl.pdf)

Suomi (FI) (99.67 KB - PDF)

**First published:**

28/06/2019

[View](/fi/documents/overview/grasustek-epar-medicine-overview_fi.pdf)

svenska (SV) (100.36 KB - PDF)

**First published:**

28/06/2019

[View](/sv/documents/overview/grasustek-epar-medicine-overview_sv.pdf)

Grasustek : EPAR - Risk management plan

English (EN) (440.8 KB - PDF)

**First published:** 28/06/2019

**Last updated:** 04/07/2024

[View](/en/documents/rmp-summary/grasustek-epar-risk-management-plan_en.pdf)

## Product information

Grasustek : EPAR - Product Information

English (EN) (927.79 KB - PDF)

**First published:** 28/06/2019

**Last updated:** 05/11/2025

[View](/en/documents/product-information/grasustek-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-671)

български (BG) (1.02 MB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/bg/documents/product-information/grasustek-epar-product-information_bg.pdf)

español (ES) (967.42 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/es/documents/product-information/grasustek-epar-product-information_es.pdf)

čeština (CS) (1.05 MB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/cs/documents/product-information/grasustek-epar-product-information_cs.pdf)

dansk (DA) (1.03 MB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/da/documents/product-information/grasustek-epar-product-information_da.pdf)

Deutsch (DE) (1008.32 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/de/documents/product-information/grasustek-epar-product-information_de.pdf)

eesti keel (ET) (901.64 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/et/documents/product-information/grasustek-epar-product-information_et.pdf)

ελληνικά (EL) (1.04 MB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/el/documents/product-information/grasustek-epar-product-information_el.pdf)

français (FR) (1012.08 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/fr/documents/product-information/grasustek-epar-product-information_fr.pdf)

hrvatski (HR) (1.11 MB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/hr/documents/product-information/grasustek-epar-product-information_hr.pdf)

íslenska (IS) (931.61 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/is/documents/product-information/grasustek-epar-product-information_is.pdf)

italiano (IT) (1016.46 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/it/documents/product-information/grasustek-epar-product-information_it.pdf)

latviešu valoda (LV) (1.03 MB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/lv/documents/product-information/grasustek-epar-product-information_lv.pdf)

lietuvių kalba (LT) (991.59 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/lt/documents/product-information/grasustek-epar-product-information_lt.pdf)

magyar (HU) (983.42 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/hu/documents/product-information/grasustek-epar-product-information_hu.pdf)

Malti (MT) (1.04 MB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/mt/documents/product-information/grasustek-epar-product-information_mt.pdf)

Nederlands (NL) (983.71 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/nl/documents/product-information/grasustek-epar-product-information_nl.pdf)

norsk (NO) (932.29 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/no/documents/product-information/grasustek-epar-product-information_no.pdf)

polski (PL) (1001.44 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/pl/documents/product-information/grasustek-epar-product-information_pl.pdf)

português (PT) (954.44 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/pt/documents/product-information/grasustek-epar-product-information_pt.pdf)

română (RO) (1.04 MB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/ro/documents/product-information/grasustek-epar-product-information_ro.pdf)

slovenčina (SK) (977.16 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/sk/documents/product-information/grasustek-epar-product-information_sk.pdf)

slovenščina (SL) (1010.01 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/sl/documents/product-information/grasustek-epar-product-information_sl.pdf)

Suomi (FI) (965.09 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/fi/documents/product-information/grasustek-epar-product-information_fi.pdf)

svenska (SV) (1011.18 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

05/11/2025

[View](/sv/documents/product-information/grasustek-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000307856 04/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Grasustek : EPAR - All authorised presentations

English (EN) (42.94 KB - PDF)

**First published:** 28/06/2019

[View](/en/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-479)

български (BG) (57.41 KB - PDF)

**First published:**

28/06/2019

[View](/bg/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.18 KB - PDF)

**First published:**

28/06/2019

[View](/es/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_es.pdf)

čeština (CS) (58.15 KB - PDF)

**First published:**

28/06/2019

[View](/cs/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (46.94 KB - PDF)

**First published:**

28/06/2019

[View](/da/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (43.95 KB - PDF)

**First published:**

28/06/2019

[View](/de/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (75.68 KB - PDF)

**First published:**

28/06/2019

[View](/et/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (59.87 KB - PDF)

**First published:**

28/06/2019

[View](/el/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_el.pdf)

français (FR) (42.57 KB - PDF)

**First published:**

28/06/2019

[View](/fr/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (53.96 KB - PDF)

**First published:**

28/06/2019

[View](/hr/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (43.4 KB - PDF)

**First published:**

28/06/2019

[View](/is/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_is.pdf)

italiano (IT) (44.87 KB - PDF)

**First published:**

28/06/2019

[View](/it/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (56.73 KB - PDF)

**First published:**

28/06/2019

[View](/lv/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (50.52 KB - PDF)

**First published:**

28/06/2019

[View](/lt/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (56.85 KB - PDF)

**First published:**

28/06/2019

[View](/hu/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (64.19 KB - PDF)

**First published:**

28/06/2019

[View](/mt/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (40.65 KB - PDF)

**First published:**

28/06/2019

[View](/nl/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (46.25 KB - PDF)

**First published:**

28/06/2019

[View](/no/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_no.pdf)

polski (PL) (59.2 KB - PDF)

**First published:**

28/06/2019

[View](/pl/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_pl.pdf)

português (PT) (44.27 KB - PDF)

**First published:**

28/06/2019

[View](/pt/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_pt.pdf)

română (RO) (55.91 KB - PDF)

**First published:**

28/06/2019

[View](/ro/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (55.78 KB - PDF)

**First published:**

28/06/2019

[View](/sk/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (56.54 KB - PDF)

**First published:**

28/06/2019

[View](/sl/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (36 KB - PDF)

**First published:**

28/06/2019

[View](/fi/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (45.03 KB - PDF)

**First published:**

28/06/2019

[View](/sv/documents/all-authorised-presentations/grasustek-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Grasustek Active substance pegfilgrastim International non-proprietary name (INN) or common name pegfilgrastim Anatomical therapeutic chemical (ATC) code L03AA13

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

## Authorisation details

EMA product number EMEA/H/C/004556

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Juta Pharma GmbH

Gutenbergstrasse 13

Opinion adopted 26/04/2019 Marketing authorisation issued 20/06/2019 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Grasustek : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (145.78 KB - PDF)

**First published:** 05/11/2025

[View](/en/documents/procedural-steps-after/grasustek-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Grasustek : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (153.18 KB - PDF)

**First published:** 31/03/2020

**Last updated:** 05/11/2025

[View](/en/documents/procedural-steps-after/grasustek-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Grasustek : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/323149/2019

English (EN) (3.86 MB - PDF)

**First published:** 28/06/2019

[View](/en/documents/assessment-report/grasustek-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Grasustek

Adopted

Reference Number: EMA/CHMP/209662/2019

English (EN) (103.86 KB - PDF)

**First published:** 26/04/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-grasustek_en.pdf)

#### News on Grasustek

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019) 26/04/2019

#### Topics

- [Biosimilars](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A45)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/11/2025

## Share this page

[Back to top](#main-content)